Clinical trials of novel therapeutics in systemic lupus erythematosus (SLE) have so far been disappointing. A high placebo response rate in these trials owing to continued use of background immunosuppressive therapy could be confounding results. Could patient stratification and minimization of entry medications improve the effect size and interpretability of SLE trials?
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Mok, C. C. Treat-to-target in systemic lupus erythematosus: are we there yet? Expert Rev. Clin. Pharmacol. 9, 675–80 (2016).
Merrill, J. T. et al. The Biomarkers of Lupus Disease study: a bold approach may mitigate interference of background immunosuppressants in clinical trials. Arthritis Rheumatol. http://dx.doi.org/10.1002/art.40086, (2017).
van Vollenhoven, R. F. et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann. Rheum. Dis. 71, 1343–1349 (2012).
Merrill, J. T. et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75, 332–340 (2016).
Merrill, J. T. et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a 24-week randomized, placebo-controlled, phase IIb study [abstract]. Arthritis Rheumatol. 68 (Suppl. 10), 12L (2016).
Gordon, C. et al. Post hoc analysis of the phase II/III APRIL-SLE study: association between response to atacicept and serum biomarkers including BLyS and APRIL. Arthritis Rheumatol. 69, 122–130 (2017).
Cambridge, G. et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67, 1011–1016 (2008).
Khamashta, M. et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75, 1909–1916 (2016).
Furie, R. et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe SLE. Arthritis Rheumatol. 69, 376–386 (2017).
Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64, 1215–1226 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Mok, C. Withdrawing standard of care therapies in SLE trials?. Nat Rev Rheumatol 13, 328–330 (2017). https://doi.org/10.1038/nrrheum.2017.59
Published:
Issue date:
DOI: https://doi.org/10.1038/nrrheum.2017.59
